> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue
- URL: https://www.fdaweb.com/since-our-last-issue-20/
- Published: 2020-05-10T12:00:00.000Z
- Updated: 2026-09-14T16:14:20.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141324

**ANI Pharmaceuticals** has signed definitive agreements to acquire a portfolio of generic products and other assets from **Amneal Pharmaceuticals** and **Impax Laboratories**. The transaction is the result of a divestiture process mandated by the Federal Trade Commission in connection with Amneal Pharmaceutical’s proposed business combination with Impax Laboratories. The parties expect to close the transaction in early May.

**Otsuka Pharmaceutical Co.** has agreed to acqure **Neurovance**, a privately held, venture-funded, clinical stage pharmaceutical company focused on attention-deficit hyperactivity disorder and related disorders.

**United Therapeutics Corp.** and **SteadyMed** have signed a definitive merger agreement under which United Therapeutics will acquire SteadyMed for $216 million. SteadyMed is a specialty pharmaceutical company focused on the development and commercialization of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs. SteadyMed's product portfolio includes Trevyent, a drug-device combination product that combines SteadyMed's two day, single use, disposable PatchPump technology with treprostinil, a vasodilatory prostacyclin analog, for the subcutaneous treatment of pulmonary arterial hypertension.